Skip to main content
Top
Published in: Current Rheumatology Reports 2/2012

01-04-2012 | PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

The Clinical Spectrum of Juvenile Idiopathic Arthritis in a Large Urban Population

Authors: Melissa S. Tesher, Karen B. Onel

Published in: Current Rheumatology Reports | Issue 2/2012

Login to get access

Abstract

Urban populations present particular challenges for medical providers. Patients are extremely diverse, with varied socioeconomic, cultural, and ethnic backgrounds. Physicians caring for children with juvenile idiopathic arthritis must be prepared to interact effectively with many types of families who bring with them varied experiences and expectations. Pediatric rheumatologists should be familiar with patient characteristics that can influence disease outcomes. Access to care is affected by place of residence, referral delays, parental education, and the child’s insurance status. Patients of different ethnic backgrounds vary in their trust of physicians and health systems. Understanding of risk in medical decision making is influenced by ethnicity as well. Adherence also varies by ethnic group, with African American patients reporting lower adherence than Caucasian patients. Issues of doctor–patient communication and use of complementary and alternative medicine are also affected by cultural factors. Especially for physicians working in a large metropolitan area, an understanding of societal factors influencing patient behavior is essential to provide optimal care for children with juvenile idiopathic arthritis.
Literature
1.
go back to reference Petty RE, Cassidy JT. Chronic arthritis in childhood. In: Cassidy, Petty, Laxer, Lindsley, editors. Textbook of pediatric rheumatology, 6th edn. Philadelphia. 2011. Petty RE, Cassidy JT. Chronic arthritis in childhood. In: Cassidy, Petty, Laxer, Lindsley, editors. Textbook of pediatric rheumatology, 6th edn. Philadelphia. 2011.
2.
go back to reference Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry. 1980;137:535–44.PubMed Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry. 1980;137:535–44.PubMed
7.
go back to reference Emery P, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.PubMedCrossRef Emery P, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.PubMedCrossRef
8.
go back to reference Breedveld C, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.PubMedCrossRef Breedveld C, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.PubMedCrossRef
9.
go back to reference Tynjala P, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomized open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12.PubMedCrossRef Tynjala P, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomized open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12.PubMedCrossRef
10.
go back to reference Magnani A, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009;36:628–34.PubMedCrossRef Magnani A, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009;36:628–34.PubMedCrossRef
11.
go back to reference Tzabarichev N, et al. Predictors of delayed referral to a pediatric rheumatology center. Arthritis Care Res. 2009;61:1367–72.CrossRef Tzabarichev N, et al. Predictors of delayed referral to a pediatric rheumatology center. Arthritis Care Res. 2009;61:1367–72.CrossRef
12.
go back to reference Foster HE, et al. Delay in access to appropriate care for children presenting with musculoskeletal symptoms and ultimately diagnosed with juvenile idiopathic arthritis. Arthritis Care Res. 2007;57:921–7.CrossRef Foster HE, et al. Delay in access to appropriate care for children presenting with musculoskeletal symptoms and ultimately diagnosed with juvenile idiopathic arthritis. Arthritis Care Res. 2007;57:921–7.CrossRef
13.
go back to reference Shiff NJ, et al. Factors associated with a longer time to access pediatric rheumatologists in Canadian children with juvenile idiopathic arthritis. J Rheumatol. 2010;37:2415–21.PubMedCrossRef Shiff NJ, et al. Factors associated with a longer time to access pediatric rheumatologists in Canadian children with juvenile idiopathic arthritis. J Rheumatol. 2010;37:2415–21.PubMedCrossRef
14.
go back to reference • Bisgaier J, Rhodes K. Auditing access to specialty care for children with public insurance. N Engl J Med. 2011;364:2324–33. Children with public insurance have starkly reduced access to pediatric subspecialty care. Many offices will not schedule a publicly insured child at all. Even in offices that accept public insurance, publicly insured patients must wait longer to be evaluated. PubMedCrossRef • Bisgaier J, Rhodes K. Auditing access to specialty care for children with public insurance. N Engl J Med. 2011;364:2324–33. Children with public insurance have starkly reduced access to pediatric subspecialty care. Many offices will not schedule a publicly insured child at all. Even in offices that accept public insurance, publicly insured patients must wait longer to be evaluated. PubMedCrossRef
15.
go back to reference Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol. 2007;34:1475–9.PubMed Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol. 2007;34:1475–9.PubMed
16.
go back to reference Ang D, et al. Patient’s ethnicity does not influence utilization of effective therapies in rheumatoid arthritis. J Rheumatol. 2006;33:870–8.PubMed Ang D, et al. Patient’s ethnicity does not influence utilization of effective therapies in rheumatoid arthritis. J Rheumatol. 2006;33:870–8.PubMed
17.
go back to reference Brunner HI, et al. Differences in disease outcomes between Medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. Arthritis Rheum. 2006;55:378–84.PubMedCrossRef Brunner HI, et al. Differences in disease outcomes between Medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. Arthritis Rheum. 2006;55:378–84.PubMedCrossRef
18.
go back to reference Levey E, et al. Health literacy in childhood arthritis (abstract). Arthritis Rheum. 2009;60 Suppl 10:716. Levey E, et al. Health literacy in childhood arthritis (abstract). Arthritis Rheum. 2009;60 Suppl 10:716.
19.
go back to reference Feldman DE, et al. Factors associated with the use of complementary and alternative medicine in juvenile idiopathic arthritis. Arthritis Rheum (Arthritis Care Res). 2004;51:527–32.CrossRef Feldman DE, et al. Factors associated with the use of complementary and alternative medicine in juvenile idiopathic arthritis. Arthritis Rheum (Arthritis Care Res). 2004;51:527–32.CrossRef
20.
go back to reference Zaman T, Agarwal S, Handa R. Complementary and alternative medicine use in rheumatoid arthritis: an audit of patients visiting a tertiary care center. Natl Med J India. 2007;20:236–9.PubMed Zaman T, Agarwal S, Handa R. Complementary and alternative medicine use in rheumatoid arthritis: an audit of patients visiting a tertiary care center. Natl Med J India. 2007;20:236–9.PubMed
21.
go back to reference Lee MS, et al. Use of complementary and alternative medicine by rheumatoid arthritis patients in Korea. Clin Rheumatol. 2008;27:29–33.PubMedCrossRef Lee MS, et al. Use of complementary and alternative medicine by rheumatoid arthritis patients in Korea. Clin Rheumatol. 2008;27:29–33.PubMedCrossRef
22.
go back to reference Zebracki K, et al. Brief report: use of complementary and alternative medicine and psychological functioning in Latino children with juvenile idiopathic arthritis or arthralgias. J Pediatr Psychol. 2007;32:1006–10.PubMedCrossRef Zebracki K, et al. Brief report: use of complementary and alternative medicine and psychological functioning in Latino children with juvenile idiopathic arthritis or arthralgias. J Pediatr Psychol. 2007;32:1006–10.PubMedCrossRef
23.
go back to reference Garcia-Gonzalez A, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27:883–9.PubMedCrossRef Garcia-Gonzalez A, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27:883–9.PubMedCrossRef
24.
go back to reference Berrios-Rivera, et al. Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2006;55:385–93.CrossRef Berrios-Rivera, et al. Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2006;55:385–93.CrossRef
25.
go back to reference • Constantinescu F, et al. Racial disparities in treatment preferences for rheumatoid arthritis. Medical Care. 2009;47:350–5. Medical decision making is notably different in African Americans compared with Caucasians. African Americans are far more risk averse and are particularly affected by increased risks of cancer due to treatments. PubMedCrossRef • Constantinescu F, et al. Racial disparities in treatment preferences for rheumatoid arthritis. Medical Care. 2009;47:350–5. Medical decision making is notably different in African Americans compared with Caucasians. African Americans are far more risk averse and are particularly affected by increased risks of cancer due to treatments. PubMedCrossRef
26.
go back to reference Constantinescu F, et al. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Care Res. 2009;61:413–8.CrossRef Constantinescu F, et al. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Care Res. 2009;61:413–8.CrossRef
Metadata
Title
The Clinical Spectrum of Juvenile Idiopathic Arthritis in a Large Urban Population
Authors
Melissa S. Tesher
Karen B. Onel
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 2/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-012-0237-7

Other articles of this Issue 2/2012

Current Rheumatology Reports 2/2012 Go to the issue

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Axial (Spinal) Gout

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Gout and Organ Transplantation

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine